tiprankstipranks
Innoviva Inc (CH:HVE)
:HVE
Switzerland Market
HVE
Innoviva
RESEARCH TOOLSreports

Innoviva (HVE) Stock Forecast & Price Target

1 Followers
See the Price Targets and Ratings of:

HVE Analyst Ratings

Strong Buy
3Ratings
Strong Buy
3 Buy
0 Hold
0 Sell
Based on 3 analysts giving stock ratings to
Innoviva
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

HVE Stock 12 Month Forecast

Average Price Target

―
Based on 3 Wall Street analysts offering 12 month price targets for Innoviva in the last 3 months. The average price target is CHF33.02 with a high forecast of CHF37.34 and a low forecast of CHF27.60. The average price target represents a ― change from the last price of ―.
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
Highest Price TargetCHF37.34Average Price TargetCHF33.02Lowest Price TargetCHF27.60
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on CH:HVE
Ram Selvaraju
H.C. Wainwright
H.C. Wainwright
CHF37.34
Buy
―
Reiterated
08/10/26
Innoviva: Strong Specialty Therapeutics Momentum and Strategic Portfolio Upside Support Reiterated Buy Rating and Unchanged $46 Price Target
Cantor Fitzgerald Analyst forecast on CH:HVE
Steven Seedhouse
Cantor Fitzgerald
Cantor Fitzgerald
CHF29.23→CHF27.6
Buy
―
Reiterated
08/06/26
Innoviva price target lowered to $34 from $36 at Cantor FitzgeraldInnoviva price target lowered to $34 from $36 at Cantor Fitzgerald
BTIG Analyst forecast on CH:HVE
Julian Harrison
BTIG
BTIG
CHF34.1
Buy
―
Reiterated
08/05/26
Innoviva: Strengthening Fundamentals, Robust Product Growth Support Unchanged $42 Price Target and Buy Rating
Goldman Sachs Analyst forecast on CH:HVE
Asad Haider
Goldman Sachs
Goldman Sachs
CHF14.61
Sell
―
Reiterated
05/06/26
Goldman Sachs Sticks to Their Sell Rating for Innoviva (INVA)
Oppenheimer Analyst forecast on CH:HVE
Trevor Allred
Oppenheimer
Oppenheimer
CHF28.41
Buy
―
Downgraded
02/26/26
Analysts Are Neutral on These Healthcare Stocks: Innoviva (INVA), Arvinas Holding Company (ARVN)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on CH:HVE
Ram Selvaraju
H.C. Wainwright
H.C. Wainwright
CHF37.34
Buy
―
Reiterated
08/10/26
Innoviva: Strong Specialty Therapeutics Momentum and Strategic Portfolio Upside Support Reiterated Buy Rating and Unchanged $46 Price Target
Cantor Fitzgerald Analyst forecast on CH:HVE
Steven Seedhouse
Cantor Fitzgerald
Cantor Fitzgerald
CHF29.23→CHF27.6
Buy
―
Reiterated
08/06/26
Innoviva price target lowered to $34 from $36 at Cantor FitzgeraldInnoviva price target lowered to $34 from $36 at Cantor Fitzgerald
BTIG Analyst forecast on CH:HVE
Julian Harrison
BTIG
BTIG
CHF34.1
Buy
―
Reiterated
08/05/26
Innoviva: Strengthening Fundamentals, Robust Product Growth Support Unchanged $42 Price Target and Buy Rating
Goldman Sachs Analyst forecast on CH:HVE
Asad Haider
Goldman Sachs
Goldman Sachs
CHF14.61
Sell
―
Reiterated
05/06/26
Goldman Sachs Sticks to Their Sell Rating for Innoviva (INVA)
Oppenheimer Analyst forecast on CH:HVE
Trevor Allred
Oppenheimer
Oppenheimer
CHF28.41
Buy
―
Downgraded
02/26/26
Analysts Are Neutral on These Healthcare Stocks: Innoviva (INVA), Arvinas Holding Company (ARVN)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
AMLXAmylyx Pharmaceuticals Inc
IMMXImmix Biopharma
JBIOJade Biosciences
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Innoviva

3 Months
Ram SelvarajuH.C. Wainwright
Success Rate
4/7 ratings generated profit
57%
Average Return
+0.31%
Copying Ram Selvaraju's trades and holding each position for 3 Months would result in 57.14% of your transactions generating a profit, with an average return of +0.31% per trade.
1 Year
Ram SelvarajuH.C. Wainwright
Success Rate
5/7 ratings generated profit
71%
Average Return
+2.09%
Copying Ram Selvaraju's trades and holding each position for 1 Year would result in 71.43% of your transactions generating a profit, with an average return of +2.09% per trade.
2 Years
Ram SelvarajuH.C. Wainwright
Success Rate
5/7 ratings generated profit
71%
Average Return
+2.01%
Copying Ram Selvaraju's trades and holding each position for 2 Years would result in 71.43% of your transactions generating a profit, with an average return of +2.01% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

HVE Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
1
3
5
5
6
Buy
4
1
1
0
0
Hold
0
0
0
0
0
Sell
0
1
1
1
0
Strong Sell
0
0
0
0
0
total
5
5
7
6
6
In the current month, HVE has received 6 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. HVE average Analyst price target in the past 3 months is 33.02.
Each month's total comprises the sum of three months' worth of ratings.

HVE Financial Forecast

HVE Earnings Forecast

Next quarter’s earnings estimate for HVE is CHF0.41 with a range of CHF0.37 to CHF0.46. The previous quarter’s EPS was -CHF0.92. HVE beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year HVE has Performed in-line its overall industry.
Next quarter’s earnings estimate for HVE is CHF0.41 with a range of CHF0.37 to CHF0.46. The previous quarter’s EPS was -CHF0.92. HVE beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year HVE has Performed in-line its overall industry.

HVE Sales Forecast

Next quarter’s sales forecast for HVE is CHF92.44M with a range of CHF84.37M to CHF107.64M. The previous quarter’s sales results were CHF99.66M. HVE beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year HVE has Performed in-line its overall industry.
Next quarter’s sales forecast for HVE is CHF92.44M with a range of CHF84.37M to CHF107.64M. The previous quarter’s sales results were CHF99.66M. HVE beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year HVE has Performed in-line its overall industry.

HVE Stock Forecast FAQ

What is CH:HVE’s average 12-month price target, according to analysts?
Based on analyst ratings, Innoviva Inc’s 12-month average price target is 33.02.
    What is CH:HVE’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for CH:HVE, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is Innoviva Inc a Buy, Sell or Hold?
        Innoviva Inc has a consensus rating of Strong Buy, which is based on 3 buy ratings, 0 hold ratings and 0 sell ratings.
          What is Innoviva Inc’s share price target?
          The average share price target for Innoviva Inc is 33.02. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is CHF37.34 ,and the lowest forecast is CHF27.60. The average share price target represents N/A Increase from the current price of N/A.
            What do analysts say about Innoviva Inc?
            Innoviva Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 3 Wall Streets Analysts.
              How can I buy shares of Innoviva Inc?
              To buy shares of CH:HVE, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.